Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia

被引：4

作者：

Chen, Tung-Sheng ^{[2
]}

Liou, Show-Yih ^{[3
]}

Wu, Hsi-Chin ^{[4
]}

Tsai, Fuu-Jen ^{[5
,6
]}

Tsai, Chang-Hai ^{[7
]}

Huang, Chih-Yang ^{[1
,2
,5
]}

Chang, Yen-Lin ^{[8
]}

机构：

[1] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 413, Taiwan

[2] China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan

[3] Formosan Blood Purificat Fdn, Taipei, Taiwan

[4] China Med Univ, Sch Med, Taichung 404, Taiwan

[5] China Med Univ, Grad Inst Chinese Med Sci, Taichung 404, Taiwan

[6] China Med Univ, Dept Pediat Med Res & Med Genet, Taichung 404, Taiwan

[7] Asia Univ, Dept Healthcare Adm, Taichung 413, Taiwan

[8] Chung Yuan Christian Univ, Dept Biomed Engn, Chungli 32023, Taiwan

来源：

INTERNATIONAL UROLOGY AND NEPHROLOGY | 2011年 / 43卷 / 02期

关键词：

Atherosclerosis; Hemodialysis; Hyperlipidemia; LDL apheresis; Oxidative stress; Uremic patients;

D O I：

10.1007/s11255-010-9722-y

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Uremic patients with hyperlipidemia are classified at high atherogenic risk due to oxidative stress induced by regular hemodialysis process (hemoincompatibility) and a high level of oxidized low-density lipoprotein (ox-LDL). This study aimed to investigate whether LDL apheresis was capable of reducing oxidative and atherogenic markers in uremic patients with hyperlipidemia. We found that oxidative metabolites (methylquanidine, dityrosine, and ox-LDL) and atherogenic markers (lipoprotein (a), LDL, and LDL/HDL ratio) were significantly reduced (P < 0.05) after LDL apheresis. On the other hand, plasma total antioxidant status (TAS) was not influenced after LDL apheresis. Our results suggest that LDL apheresis reduces oxidative and atherogenic markers and do not influence plasma TAS in uremic patients with hyperlipidemia. This may lead to a decreased risk of atherosclerosis in these patients. However, supplementation of dietary proteins may be necessary because of the removal of some "useful" proteins (e.g., albumin and globulin) after LDL apheresis.

引用

页码：471 / 474

页数：4

共 13 条

[1] Effect of dialysis membrane biocompatibility on polymorphonuclear granulocyte activity in dialysis patients [J].

Banche, Giuliana ;

Allizond, Valeria ;

Giacchino, Franca ;

Mandras, Narcisa ;

Roana, Janira ;

Bonello, Franco ;

Belardi, Paola ;

Tullio, Vivian ;

Merlino, Chiara ;

Carlone, Nicola ;

Cuffini, Anna Maria .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (12) :3532-3538

[2] 26 Years of LDL-Apheresis: A review of experience [J].

Borberg, H. .

TRANSFUSION AND APHERESIS SCIENCE, 2009, 41 (01) :49-59

[3]

COLLIBENUOUR EE, 2009, INT UROL NEPHRO 1001

[4]

de Sá HMPO, 2001, AM J NEPHROL, V21, P264

[5] Score Model for the Evaluation of Dialysis Membrane Hemocompatibility [J].

Erlenkoetter, Ansgar ;

Endres, Pia ;

Nederlof, Bernd ;

Hornig, Carsten ;

Vienken, Joerg .

ARTIFICIAL ORGANS, 2008, 32 (12) :962-969

[6] Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis [J].

Ishigaki, Yasushi ;

Katagiri, Hideki ;

Gao, Junhong ;

Yamada, Tetsuya ;

Imai, Junta ;

Uno, Kenji ;

Hasegawa, Yutaka ;

Kaneko, Keizo ;

Ogihara, Takehide ;

Ishihara, Hisamitsu ;

Sato, Yuko ;

Takikawa, Kenji ;

Nishimichi, Norihisa ;

Matsuda, Haruo ;

Sawamura, Tatsuya ;

Oka, Yoshitomo .

CIRCULATION, 2008, 118 (01) :75-83

[7] Applications of LDL-apheresis in nephrology [J].

Kobayashi, Shuzo .

CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2008, 12 (01) :9-15

[8]

Mehta Puja K, 2009, Curr Treat Options Cardiovasc Med, V11, P279

[9]

OPTRNY K, 2006, HEMODIAL INT, V10, P201

[10]

RAFFAELLA S, 1995, BRIT J PHARMACOL, V115, P510

← 1 2 →